Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293500 | 1.00 | LMNA (0.42) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL808888 | 0.85 | LMNA (0.47) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL808887 | 0.85 | LMNA (0.47) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL1073355 | 0.84 | LMNA (0.44) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL1073358 | 0.84 | LMNA (0.44) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL9862124 | 0.84 | LMNA (0.38) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL294875 | 0.82 | LMNA (0.60) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL9862105 | 0.81 | LMNA (0.42) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL10828251 | 0.81 | LMNA (0.42) | LMNATSHRTDP1CYP1A2CYP2C19 | |
| SCHEMBL8613546 | 0.79 | LMNA (0.40) | LMNATSHRTDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1683783-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1683782-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1120402-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1683782-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1683783-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-7009079-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO., LTD. | 2005-04-28 | — | — | US | disclosed |
| US-6670500-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-10 | — | — | US | disclosed |
| EP-1120402-A2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
| US-4420435-A | Alpha-hydroxy-phosphonic acid esters | BAYER AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | disclosed |
| US-4358409-A | Preparation of styryl cyclopropane insecticide intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1982-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, CYP1A1, NFXL1 | LMNA 4567/4885TSHR 1375/4885TDP1 4523/4885 |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, XDH, NFXL1 | LMNA 4559/4885TSHR 2499/4885TDP1 3929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.